Lantern Pharma Inc
LTRN
NSC
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
5.46
USD
0.19
(3.61%)
Optionable: Yes Market Cap: 55 M 90-day average vol: 0
Previous close: 5.27 Open: 5.25 Bid: 5.63 Ask: 5.63
52 week range
0.00 0.00
Last updated: Monday 8th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 0.00 |
Price per Book TTM ($) | 0.83 |
PE Ratio (TTM) | -4.00 |
Book Value per Share ($) | 6.03 |
5 Year PE Range | -13.9 , -7.1 |
Returns
7 Day Return | 8.55% | |
1 Month Return | -5.70% | |
3 Month Return | -4.55% | |
1 Year Return | -60.58% | |
3 Year Return | -63.48% | |
5 Year Return | -63.48% | |
YTD Return | -31.58% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 53.57 |
14 Day SMA ($) | 5.23 |
14 Day EMA ($) | 5.25 |
Money Flow Index | 53.88 |
Average True Range | 0.34 |
50 Day SMA ($) | 5.40 |
200 Day SMA ($) | 6.85 |
ADX | 20.50 |
MACD | -0.08 |
Growth
Free Cash Flow QoQ Growth | 63.20% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 22.58% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | 0.00% |
Chart
News
Lantern Pharma Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
Yahoo Finance 3/3/2022
Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio
Yahoo Finance 2/15/2022
Sanders Morris Harris Llc Buys Roth CH Acquisition V Co, The Walt Disney Co, Mastercard Inc, ...
Yahoo Finance 2/2/2022
RedChip Partners with Benzinga to Host Exclusive Small-Cap CEO Interview Series on January 28
Yahoo Finance 1/26/2022
Lantern Pharma up 11% on Rare Pediatric Disease and Orphan Drug tag for LP-184 for ATRT
Seeking Alpha 1/24/2022
LTRN: Multiple Collaborations Illuminating Way Forward
Yahoo Finance 1/20/2022
Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors
Yahoo Finance 1/18/2022
Lantern Pharma rises 9% on team up with National Cancer Institute for drug candidates
Seeking Alpha 1/12/2022
Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284
Yahoo Finance 1/12/2022
Lantern Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference
Yahoo Finance 1/4/2022
Lantern Pharma presents positive LP-284 data in hematologic cancers at ASH 2021
Seeking Alpha 12/14/2021
Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting
Yahoo Finance 12/14/2021
Lantern Pharma announces $7M share repurchase authorization
Seeking Alpha 11/22/2021
Lantern Pharma Announces Share Repurchase Program
Yahoo Finance 11/22/2021
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: -4.267
Financials
LTRN Income Statement
Annual
| Invalid date | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | |
| Cost of sales | 2544 | -1627 | -3388 | -147267 | |
| Gross operating profit | 0 | 0 | 0 | 0 | |
| Selling Gen & administrative expense | 1 M | 1 M | 4 M | 5 M | |
| Research & development expense | 572095 | 953185 | 2 M | 8 M | |
| Operating income | -2 M | -2 M | -6 M | -13 M | |
| floaterest income | 0 | 0 | 0 | 0 | |
| floaterest expense | 0 | 0 | 0 | 0 | |
| Other income net | 0 | 0 | 0 | 160550 | |
| Pre-tax Income (EBT) | -2 M | -2 M | -6 M | -12 M | |
| Income taxes | 0 | 0 | 0 | 0 | |
| Net income from total operations | -2 M | -2 M | -6 M | -12 M | |
| Minority floaterest | 0 | 0 | 0 | 0 | |
| Total net income | -2 M | -2 M | -6 M | -12 M | |
| Preferred dividends | N/A | N/A | N/A | N/A | |
| Net income available for common | -2 M | -2 M | -6 M | -12 M | |
| Depreciation | -2544 | 1627 | 3388 | 147267 | |
| Amortization | 0 | 0 | 0 | 0 | |
| Operating income before depreciation (EBITDA) | -2 M | -2 M | -6 M | -13 M | |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | |
| Basic EPS total | -0.28 | -0.39 | -1.37 | -1.13 | |
| Diluted EPS total | -0.28 | -0.39 | -1.37 | -1.13 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!